Replay available

Gossamer Bio (NASDAQ:GOSS) Q1 2019 Earnings Call

Gossamer Bio (NASDAQ:GOSS) Q1 2019 earnings call, held 2019-05-14. Watch the replay and read the transcript on 6ix.

Tue, May 14, 2019 at 8:30 AMendedReplay
Gossamer Bio (NASDAQ:GOSS) Q1 2019 Earnings Call
Company
Gossamer Bio, Inc. (NASDAQ:GOSS)
Period
Q1 2019 earnings call
Date
Tue, May 14, 2019, 8:30 AM ET
Replay
Watch the replay on this page · 43 min

On 6ix: 6ix.com/event/gossamer-bio-inc-goss-q1-2019-earnings-call

Replay

Transcript

Automated transcript · Written by software from the replay's audio. It can mishear names and figures; the replay is the record.

0:00 Good day, ladies and gentlemen. Your conference call will begin in approximately two minutes. Thank you for your patience. . . . . . . .

1:18 . . . Thank you for watching. Good morning and welcome to the Gossamer Bio first quarter 2019 earnings call.

2:09 Today's call will feature updates from Gossamer Bio management's team, followed by a question and answer session. I will now turn the call over to Gossamer's chief financial officer, Bryan Giraudo. Bryan?

2:22 Thank you, operator, and thank you all for joining us this morning. With me on today's call is Gossamer's co-founder and chief executive officer, Dr. Sheila Gujarati. Earlier this morning, Gossamer issued a press release announcing its financial results for the first quarter ended March 31, 2019, and provided a corporate update. Please note that certain information discussed on the call today is covered under the safe harbor provision of the Private Securities Litigation Reform Act. We caution listeners that during this call, Gossamer management will be making forward-looking statements. Actual results may differ materially from those stated or implied by these forward-looking statements due to risks and uncertainties associated with the company's business. These forward-looking statements are qualified by the statements contained in Gossamer's news releases, SEC filings, including the annual report on Form 10-K and subsequent filings.

3:14 This conference call also contains time-sensitive information that may be accurate for only a limited period of time. Gossamer Bio undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this conference call. Now with all of those wonderful remarks, I will turn it over to Sheila. Sheila?

3:34 Thank you, Bryan, and good morning to everyone joining us on today's call. The recent months have been an exciting time for Gossamer, and we have had an exceptionally busy start to 2019. On today's call, I'm going to walk you through updates and milestones achieved for our soon-to-be four clinical stage programs, and then I will hand it back over to Bryan to go over our financial results for the quarter. Since our IPO was closed in February, We have rapidly moved towards our goal of becoming a leader in immunology, inflammation, and oncology. We are setting the foundation this year for multiple data readouts expected in 2020. Let us start with our most advanced clinical stage product candidate, GB001, an oral BP2 antagonist, which is being developed for eosinophilic asthma and other allergic conditions, including chronic sinusitis, both with and without nasal polyps, and Chronic Spontaneous Urticaria.

4:31 As we have previously announced, our Phase IIb trial in moderate to severe eosinophilic asthma, known as a LIDA study, is currently enrolling patients and we remain on track to trigger an interim analysis in the first half of 2020. The LIDA study is testing three once-daily doses of GV001, 20, 40 and 60 milligrams against placebo in a 24-week study. All patients will remain on background therapy throughout the study, and the primary endpoint is a composite measure known as asthma worsening. If the interim analysis of the study in the first half of 2020 is positive, we plan to begin the first of two Phase III trials designed to support NDA registration with the FDA.

5:16 In February, at this QADI meeting in San Francisco, Dr. Hector Ortega, who is leading the development of GB001 in Gossamer, presented results of a post-hoc analysis of a GB001 study in patients with mild to moderate, partly controlled atopic asthma. Findings presented suggested that fractional-tailed nitric oxide, also known as phenol, could serve as a useful prognostic marker for treatment response to GB001. In addition to elevated eosinophils, which is the marker we are currently using to involve a LIDA study, In the analysis, we found marked reductions in phenol levels, as well as greater numeric improvements in lung function and asthma control relative to placebo in patients with high baseline phenol as compared to patients with low baseline phenol. We are excited about these results and the potential implications for future development of GB001.

6:11 We have also started to execute our strategy to develop GB001 in other allergic conditions driven by type 2 cytokine biology, where GB001 could potentially be first in class. We are excited to inform you that we have begun screening patients in our Phase II proof-of-concept study in chronic rhinocytosis, also known as the TITAN study. We expect to dose the first patient in the study later in the second quarter. The TITAN study will involve patients both with and without nasal polyps, both of which represent populations of high unmet needs, were there a significant overlap of the asthma population and a lack of effective treatment options for patients failing to respond to intranasal steroids. We plan to enroll approximately 100 patients in the study, which is designed to measure the effect of GB001 on the sinonasal outcome test, or SNOT22 score, after 16 weeks of treatment in patients who are refractory to intranasal steroids.

7:09 The SNOT22 endpoint has relevance for both patients with and without nasal polyps. and we also plan on assessing polyp-specific endpoints, such as the nasal polyp score, in a subset of patients with polyps as a key secondary endpoint. We expect this study to read out in 2020. Additionally, we are on track to initiate another phase two proof of concept study of GB001 and chronic spontaneous urticaria, or CSU, later this year. Patients with CSU have poor quality of life and little is available to those that don't respond to antihistamines with the injectable biologic Xolair as the only approved therapy. We also expect that trial to read out in 2020. We are very excited by the potential for GB001 to be the oral treatment of choice across multiple allergic indications, and we look forward to 2020 as a data-heavy-rich year for the program.

8:06 Let us now move on to our second most advanced clinical stage product candidate, GB002, which is an inhaled PDGFR inhibitor we are developing for the treatment of pulmonary arterial hypertension, also known as PAH. PAH is an orphan disease with high medical needs. While there are currently three classes of vasodilator therapies available to PAH patients, PAH remains a progressive and often fatal disease. GB002 could potentially be the first drug in a new therapeutic class, and we believe it could provide disease-modifying effects to patients. GP002 was rationally designed after promising clinical results in PAH were observed with a multi-kinase inhibitor imatinib, which is currently marketed in oncology indications under the brand name Gleevec. Imatinib demonstrated very promising efficacy in the Phase III IMPRESS study, but it was hampered by serious safety concerns and was ultimately not for the development in PAH.

9:05 GP002 was designed to be potent and selective, and Richard Aranda. Thank you. Thank you. To attempt to avoid the systemic toxicities seen in the MATNIF studies, we are developing GB002 as an inhaled therapeutic delivered by a simple-to-use dry powder inhaler. We believe that the inhaled formulation provides the drug locally to blood vessels in the lungs where the disease is present and spares the patient of systemic exposure and death toxicity.

9:53 We have completed dosing with GB002 in Phase 1 safety studies and normal healthy volunteers, in which GB002 was well tolerated with no significant adverse events observed to date. We expect to begin site initiation and patient screening for our Phase 1b and PAH patients later in the second quarter. The Phase 1b will be an exploratory, translational two-week study in up to 24 patients, followed by an open-label extension, which we plan to initiate later in the year. We hope to generate interesting target engagement and biomarker measures from this study, and we anticipate a readout in the first half of 2020. Moving right along to our third clinical stage asset, GB004 is an oral HIP1-alpha stabilizer for the treatment of inflammatory bowel disease, including ulcerative colitis, or UC.

10:47 IBD is a disease we know very well, given our team's experience with a number of IBD therapeutics, including Ozanamon. And though it is an increasingly crowded space, long-term clinical remission and mucosal healing rates for IBD patients remain low, and thus we believe there is still significant unmet need for these patients. The clinicians we've spoken to in designing our clinical program have been very excited by GP004's oral route of administration, and the novel differentiated mechanism of action we're pursuing. GP004 is a gut-targeted prolohydroxylase inhibitor designed to preferentially stabilize HIP-1 alpha, a transcription factor involved in the body's protective response to low oxygen levels.

11:34 It has been demonstrated that lower than normal oxygen levels are present in the intestinal tissue of IBD patients, which contributes to the disruption of the mucosal barrier and perpetuates the inflammatory process. In preclinical IBD models, hip one alpha stabilization is known to induce protective mechanisms involved in promoting barrier function, epithelial reconstitution and reducing inflammation, ultimately resulting in healing of the mucosa. While we have also seen some potentially important immunomodulatory effects of GB004 in preclinical models, GP004's novel mechanism of action is unique in that it enhances epithelial barrier function and repair rather than act through purely immunosuppressive mechanisms.

12:23 After running Phase 1 studies in healthy volunteers outside of the U.S., we now have an active IND and are very pleased to announce that we have begun screening in a Phase 1B trial in patients with active mild to moderate UC. We expect to dose our first patient in the study in the second quarter. We will begin dosing patients for four weeks, then potentially increase the length of dosing to eight weeks following the completion of preclinical studies. The study is designed to demonstrate activity in UC patients based on target engagement, changes in gene expression, and epithelial barrier restoration, and potential UC symptom improvement. We anticipate that this trial will have an initial readout in the first half of 2020.

13:09 Finally, GB1275 is our oral CD11B modulator for the treatment of cancer. GB1275 is our first immuno-oncology product candidate, and we're very excited about the preclinical data it has generated in difficult-to-treat tumor models. Our strategy in immuno-oncology is to focus on tumor types that have either primary or secondary resistance to anti-PD-1 immune checkpoint therapy. A key factor in both forms of resistance are the innate immune cells, such as myeloid-derived suppressor cells, or MDSCs, and tumor-associated macrophages, or CAMs, recruited by the tumor to suppress the immune response. In preclinical studies, modulation of CD11B with GB1275 reduced trafficking of those immune cells into tumors and, importantly, also converted or repolarized them from a suppressive state to a pro-inflammatory state.

14:09 We have recently submitted our IND to the FDA, and subject to the FDA's review, we plan to initiate a Phase I-II study in advanced solid tumor indications in the second half of 2019. The Phase I-II study will investigate GB1275 and multiple tumor types, including pancreatic, gastric, colorectal, esophageal, and triple negative breast. These are all tumor types where immunosuppressive biology and CD11B expression in cells is prevalent. The Phase I portion of the study consists of dose escalation of GB1275 monotherapy, followed by dose escalation combinations with anti-PD1 therapy or chemotherapy.

14:54 When we reach a recommended Phase II dose, we plan to open, in the same protocol, three Phase II expansion cohorts with anti-PD1 therapy or chemotherapy and first-line metastatic pancreatic cancer, second-line or greater microsatellite stable colorectal cancer, and second-line or greater PD-L1 positive gastric or gastroesophageal cancer. I'm very proud of the work our team has done to add GB1275 to our portfolio of clinical stage product candidates, and we look forward to bringing GB1275 into the clinic later this year. It has been a very busy few months, and we are proud of the progress we have made in building out a diverse portfolio of assets targeting indications with high unmet needs.

15:44 Before I turn the call back over to Bryan, I also want to highlight that we will be hosting a fireside chat this afternoon at 4 p.m. Eastern Time at the Bank of America Merrill Lynch Healthcare Conference and that event will be webcast live for all those who would like to join. Please see the investor page on the Gossamer Bio website for further details. With that, I would now like to turn the call back over to Bryan Giraudo for a financial update. Bryan?

16:11 Thank you, Sheila. I will give a brief summary of our financing activities over the past few months before going over the results for the quarter. As previously announced, in February, we closed our initial public offering, in which we raised over $291 million in net proceeds. Following the close of our IPO, we announced a $150 million debt facility led by MidCap Financial. 30 million of that facility was taken down at the closing of the agreement and 120 million will be available to Gossamer subject to the achievement of certain clinical development milestones and other customary conditions. With these two financings, Gossamer is in a very strong cash position with our cash runway extending into the second half of 2021. Now on to the financial results for the first quarter. We ended the quarter with $492.5 million of cash and cash equivalents which also included a $11 million interest in securities receivable which we received following the quarter end.

17:09 This does not reflect the initial proceeds we received at the signing of the MidCap facility. Research and development expenses were approximately $25 million in the quarter which reflects a ramp up of expenses for GB001, GB002, and GB004. In-process R&D expenses which consist of costs related to the acquisition and licensing of our product candidates were approximately $1 million in the quarter. G&A expenses were $8 million in the quarter with nearly $2 million of that in stock-based compensation. Our net loss for the quarter was $32.6 million, equating to $0.90 per share. With that, I'll turn the call back over to Sheila to offer some closing comments before we open the line for questions and answers. Sheila?

17:54 Thank you, Bryan. At Gossamer Bio, we are thrilled with the momentum we have generated in developing our multiple product candidates that we believe have the potential to significantly better the lives of patients and their families. We are also incredibly proud of our great team who is realizing our vision at Gossamer Bio. Our strong financial position allows us to continue to advance our science for the benefit of patients, caregivers, physicians, employees, and shareholders alike. Thank you for taking the time to join us today and for your continued support. With that, I will now turn the call over to the operator to begin the question and answer session. Operator? Thank you. Ladies and gentlemen, if you have a question at this time, please press the star, then the one key on your touchtone telephone.

18:43 If your question has been answered or you wish to remove yourself from the queue, please press the pound key. Again, if you'd like to ask a question, press the star, then the one key on your touch-tone telephone. And our first question comes from Ying Hong with Bank of America. Merrill Lynch, your line is open.

19:05 Hi, Monique. Thanks for taking my questions, and congrats on all your progress. So maybe two quick ones for Sheila. First, one is All the investors are looking forward to the results from Novartis on the first batch of clinical data from phase 3 trials for Febipiprin. So can you talk about the read-through? If it's positive, what does that mean for GP001, which is obvious, I guess, and then which is negative, how should we think about any comparative advantage your compound GP001 may have against Febipiprin here? And then secondly, you completed the... Phase 1 trial for GB002 in healthy volunteers. Can you talk about the findings in terms of the PK dose response and PD besides the fact that there's no SAE from the trial?

19:55 And then quickly for Brian, can you talk about why you took that, I guess, financing capacity from MCAT? Is it because you need additional cash to support ongoing development or not? Thank you.

20:12 Thank you. Great questions. Yeah, so let's start with the Novartis Study Pit Print Program. We are also very much looking forward to their Phase 3 data readouts. Just to remind everyone, they have a large Phase 3 program actually consisting of six Phase 3 trials within asthma. Four of those Phase 3 trials are reading out later this year. In terms of their recent guidance, that is still on track. and so we are anticipating they have two exacerbation trials that we'll be reading out in the September and December timeframe and then two FEV1 or lung function trials reading out around November. So these are the Lustre and the Zeal trials that we'll be reading out. and so it says those trials are positive in the moderate to severe asthmatic population including a subgroup of eosinophil high patients.

21:05 That is very much a validation of the mechanism of BP2 antagonism and so I think that would be positive to our program because of the similar We are very much looking forward to that. They are going into a broad moderate to severe eosinophilic asthma population, but their primary endpoint is on the subgroup of high eosinophils or Th2 high subgroups. and we do know that they have stated that that is their base case in terms of where they think they will see positive data, which is very consistent with the way we view the biologic relevance and activity for DP2 antagonism and for GB001. Now we do have some points of differentiation to FETI-PIPPRINT.

21:52 We have a very potent selective molecule with GB001 in that we have high binding infinity to the DP2 receptor. We also have prolonged receptor residence time, which is greater than what has been observed by the PIP grant. We have about an 18 to 20 minute receptor residence time. What Novartis has published is around 12 minutes, and we do think that's very important for the mechanism of action here as we inhibit PGD2 internalization of the DP2 receptor in a very effective manner. And also very importantly, We have, we think, greater PK characteristics for GV001 in that the footprint has to go up to 150 and 450 milligrams to really reach their exposure that they think are clinically efficacious.

22:42 and we are able to achieve that with much lower dosing and we think actually better coverage over a 24-hour period than those dose levels. So there is a potential that we could show really potentially better efficacy in the clinic in the case that Febuprofen doesn't meet their mark. So those are very important characteristics for us for GB001. We will be watching closely to see what the clinical efficacy and safety profile is coming out of the FabioCrip Rant Phase 3 trials. And, of course, we are greatly anticipating seeing our interim data in the first half of 2020, followed by the full data readout later that year. So that's the first question.

23:28 With that, I'm going to move on to the second question, unless you have any other further follow-ups. The Phase 1 for GB002, yes, that was a very exciting trial for us because we obviously took the inhaled formulation of GB002 into normal healthy volunteers. both the single-setting dose cohorts and multiple-setting dose cohorts. And we are, again, very pleased with the PK profile that we're seeing coming out of that study. We are seeing absorption rapidly into systemic circulation but with a fast clearance, so we have a short half-life. We also do not see a dose accumulation upon multiple dosing, which was important for us to make sure that we were ruling that out. So the profile of really having increased lung exposure compared to systemic exposure is being confirmed in the clinic. And we're looking forward to taking the dose regimen into now PEH patients in the Phase 1B trial to confirm the PK characteristics that we're seeing in the normal healthy volunteers.

24:30 And again, just to remind you, we expect to have several fold higher exposure in the lungs compared to the systemic exposure. which is really the crux of the differentiation that you want to maximize efficacy and minimize systemic toxicities. And then the safety and tolerability profile were very robust in that we did not see any significant adverse events. And the inhaled formulation was very well tolerated in normal healthy volunteers. So again, that's very nice data for us in confirming that the dry powder inhaler and its formulation is being well tolerated. With that, I'll have Bryan answer the third question.

25:07 Thank you, Ian, on the question in regards to the mid-cap debt. We put that in place purely as a means to ensure that the runway was very, very sufficient well into 2021. As I had said, with seven milestones next year, we wanted to make sure that we could deliver that news and those milestones to our investors and still be able to communicate robustness of the balance sheets to trigger the next level of clinical work that would be on the come. So it was really a means to ensure long-term runway and access to capital.

25:44 Great. Thank you very much. Thank you. And our next question comes from Joseph Schwartz with SVB. Larry, your line is open.

25:56 Great. Thanks very much, and congrats as well. I was wondering if you could talk about the signals that you'll be looking for to see if GB001 has activity in some of the newer areas you've outlined going into, such as chronic rhinocytositis with and without nasal polyps and chronic spontaneous urticaria. It seems like development in some of these spaces has been heating up more. across pharma, too. So has the increased activity made execution a challenge in any way?

26:35 Yes, thanks, Joe. Well, again, we're excited about these additional indications we're going after. And it is actually more whiteface in that, you know, we are the only oral that's really moving forward into both chronic sinusitis with and without polyps. and the chronic urticaria disease area. So I'll start with chronic linusitis, again, with and without polyps. And here the study is really designed to enroll patients in both populations. Now the primary endpoint is looking at the SNOT-22 clinical outcome measure, which is a 22 outcome point questionnaire. and we're going to be basically looking for what we consider clinically meaningful improvement looking at those outcome measures and that's very relevant for patients either with or without PALS because it really gets at a lot of the nasal symptoms that these patients have including nasal obstruction, congestion, loss of the sense of smell and other symptoms that are very pertinent and really debilitating for these patients.

27:39 In addition, as I mentioned, we will be looking at the nasal polyp score, and this is a validated endpoint that actually is being brought forward with Dupilumab in their Phase III trials. Dupilumab has applied to the FDA as a supplemental BLA. That application has been accepted, and it is under priority review at this time. and so they have looked at the endpoints of nasal obstruction and congestion as well as looking at the reduction in nasal polyp score and so that is something also that we're very keen to understand in the subgroup of patients that have nasal polyp. So we are looking again for what we consider clinically meaningful improvement or reduction in that nasal polyp score as well.

28:25 So, you know, and then we have a number of other outcome measures that are exploratory but very exciting We're looking at CT scan outcomes, so we're looking at the reduction of opacification of the sinuses with CT. We're also looking at quality of life questions coming out of this area and really looking at aspects of chronic rhinositis in terms of chronic rhinositis exacerbations requiring oral steroids or emergency room visits, things of that nature, which is similar to how we think about severe exacerbations in asthma. So, you know, again, robust study from our perspective in that it's studying two different populations, and between all the different endpoints we're going to be looking at, we think we'll get a nice read on what is our activity level here.

29:14 And there's a significant amount of TH2 biology that's really driving both of these populations, so we think that makes sense. Now, the second indication is chronic urticaria. And just as you had asked about the enrollment challenges, With chronic rhinositis, we're pretty excited. We don't know of any really significant competitors out there right now, especially with an oral.

29:38 We think we can enroll that trial and stay on our timeline. We don't have any significant concerns at that point. Again, we have begun screening patients here and are very excited to enroll a patient later in the quarter. For chronic urticaria, again, well-validated pathway, development pathway, we have Zoller approved there, lidaluzumab, the next generation anti-IG antibodies coming forward from Novartis and two large VHG trials. And, you know, there are other biologics that are doing some exploratory work within urticaria. So here we're looking at the urticaria activity score 7 and the urticaria control test. So we have a pretty good idea of what would be a clinically significant or relevant improvement in urticaria symptoms. And we don't have to do a very large study in sample size to actually get a pretty good read on clinical activity and efficacy.

30:35 And here, again, while ligalizumab is going forward in a very large Phase III program, we do think there's a lot of excitement around an oral. And so, you know, we are excited. There is a BTK inhibitor that is being studied in urticaria as well, but there's a lot of excitement around the DP2 receptor biology, especially when it comes to the inhibition of basophil and mast cell function, which are the key cell types within urticaria. So we're getting very good receptivity from the KOLs and investigators in this space, and we don't anticipate a significant challenge in recruiting this trial.

31:10 That's really helpful, thanks. And if I could ask one on GB001 and asthma. For the interim analysis that I think is guided for the first half of 2020, what data will you evaluate for the interim analysis versus the final analysis? And is there any opportunity to adjust course in between the two analyses?

31:31 Yeah, it's going to be a pretty robust data readout. This is a substantially sized study, so we'll have about 320 patients. So we'll have 24 weeks worth of data, and of course we'll have even more patients that will have additional data of varying duration, less than 24 weeks. And the interim analysis was really designed to look at efficacy across a number of endpoints. So our primary endpoint is looking at asthma worsening. So that's a clinical composite outcome measure, very similar to what we studied in the Cajun Phase II trial and other clinical trials where you really look at different measures of Refugee Medication Use, of course, exacerbations, worsening in lung function, and the like. So we'll look at the totality of the outcome measure because of asthma worsening reduction, as well as each subcomponent of that composite measure. And, of course, we'll look at lung function as measured by FEV1, as well as peak flow. and then we'll look at a number of other safety, tolerability, PK, exposure and so I think we're pretty excited about the robust type of data readout we'll get from that trial.

32:45 Now the full data readout will be of course all 480 patients with 24 weeks worth of data and this analysis is not really designed to change the design or the conduct of the Phase IIb trial. It's really actually more of an administrative analysis that helps us with Phase 3 planning and the Phase 3 initiation that we may want to pursue if the data is positive that really allows for operational efficiency and allows us to quickly go into a Phase 3 program and continue to capitalize on the recruitment and the robust recruitment we're seeing right now in the Phase 2 VLIDA trial.

33:22 Great. Thanks for the added information. Thanks, Bill. Thank you. And our next question comes from Jeff Meacham with Barclays. Your line is open. Hey, guys. This is Scott on for Jeff. Thanks for taking our question. I'm just wondering, as you get closer to commercializing the 001 asset in asthma, have you thought about how you're going to define the moderate persistent market for physicians and integrate yourself before the biologics that are in the severe persistent category? And maybe what percentage of The intermittent or moderate patients, can you capture before they move directly to that severe persistent category? Thanks.

34:01 Thanks, Scott. Really great questions. We are spending actually quite a bit of time understanding this aspect of the market in a much more robust manner, including looking at claims database analysis and really getting that type of insight to your point. And we do think this is really where a lot of the market opportunity exists for GB001. and that there is a substantial amount of patients that are considered moderate. Gina, four or five, that is really continuing to have active symptomatology despite being on inhaled corticosteroids and one other controller medication that we think is not being addressed by the biologic therapies that are available and approved and on the market today. But these patients are in high need.

34:49 They do not have adequate asthma control. and they frankly don't want to go on telebiologic. They're not very adherent to their ICS. We're looking at even adherence rates with inhaled corticosteroids and it's pretty poor. As you know, there's actually 50% rates of what we call non-adherence or non-compliance. And understanding who are the physicians who take care of these patients as well. And we do see a mix of allergists, pulmonologists and really a subgroup of primary care physicians who we think we could also target with an oral treatment. and so it is around that positioning of our profile where we will have we think really robust efficacy similar to biologic safety and tolerability that will be improved and that oral once a day convenient administration that does not require injectable or infusions it's not administered in the office and again it's really greatly anticipated and needed by patients and their prescribing physicians so we do think we have a We're getting a better idea of how to target that moderate persistent category before the more severe persistent asthma comes on.

35:59 And that's a significant market potential in terms of numbers of patients. Great. Thanks so much. Sure. Thank you, Scott. Thank you. And our next question comes from Josh Shimmer with Evacor. Your line is open.

36:20 Thanks for taking the questions. First on O2, could you elaborate on the specific relevant biomarkers or disease outcome measures that you're looking for in terms of the magnitude of effect of the signal in a Phase II trial for advancing the program? The same question for O4 with the addition of the gene expression markers. And then third question, how are you thinking about your capacity and optimal timing for additional biz dev efforts considering that over the next year or so you're going to have a number of of data points that will really inflect the direction that the company is headed. Thanks.

36:56 Great. Thanks, Josh. Yeah, I'm happy to expand on that one of the occurrences. So for 002, we actually have a number of very interesting biomarkers that we can study in the Phase 1B translational study and where we have also seen good efficacy or activity with imatinib. So there's actually some precedent there in terms of characterization of effect on these markers. So a very important marker in this space is what we call the NT-proBNP level, which is the brain natriuretic peptide, which is a real marker of right heart strain in this patient population. And so that's a key biomarker that we're very excited about studying. Again, imatinib did show some nice reductions in proBNP levels.

37:40 And preclinically, in our own animal models, we've seen a very nice reduction in proBNP and actually greater than what we've seen with the matinib. So that's a key marker for us. In addition, as you probably know in PAH, imaging can be very relevant and very helpful in understanding the efficacy and actually there's a lot of movement to imaging as a non-invasive measure to look at effects on especially right heart function, strain and muscle mass. And so cardiac MRIs and cardiac echocardiograms are important for us, and so I think we're leaning more towards the MRI field, and that is, again, more robust outcome measures, but that's another key imaging measure that we're going to be looking at, especially with continued treatment of these patients. And then we'll be looking at PDGF gene expression profiles.

38:35 We actually are looking at some other target engagement assays, which get at some of the other kinases that we may hit just to give us an idea of, again, target engagement. So I think a pretty nice group of biomarkers that we'll be looking at to see and assess the clinical activity, especially with the high lung exposure we think we'll be achieving in the clinic. So that's 002. I'll jump to 004. and again here some really exciting target engagement data looking at HIP-1-alpha levels as well as the HIP-1-alpha gene expression signature that we've been looking at pre-clinically. And, you know, we have seen some nice data on this, even looking at the phase one normal healthy bond series where we did colonic biopsies. We actually saw some target engagement there in that population.

39:25 And so that's something that we think we'll continue to study in the ulcerative colitis population. But there, because we're enrolling patients who have active histology, and we're looking at a histopathology index that's been developed by Robarts to see what is the impact on that histology over time. So patients can only get into the study if they have active histology on screening. So that'll be, again, a nice measure of clinical activity. And then because we're doing endoscopy, either colonoscopies or flex sigmoidoscopies, we'll be looking at the mucosa directly and we'll be able to really assess the Mayo score. and with four or eight weeks of treatment, that's really the induction timeframe of where we could start seeing some clinical improvement.

40:13 So a lot of data will be coming out of that Phase 1B trial. So again, both pretty exciting studies from our perspective and we think we should get some nice data readouts by first half of 2020. And then lastly, on business development, we are continuing to do active business development. You are right. We are executing on a number of clinical programs. And so that's really where our focus has been. And we are very focused on execution right now to make sure we meet our milestones. And we're generating clinical data not only on GB001 across the three indications, but really on our pipeline as well for 2, 4, and 1275. and that we will have data readout that will be meaningful coming out of these programs in that same timeframe as the 001 data readout. So that's obviously top of mind for us but we do have a very active business development effort. We get a lot of inquiries and we see a lot of programs that we're interested in. What we've guided to right now is that we're primarily looking at programs in the late stage research arena and those are programs that will to our research portfolio and pipeline. And we'll be coming into that clinic in that 2021 and 22 timeframe. So I think that's really where most of our business development efforts have been, looking at programs that we're excited about, either because the target biology that is known to us, that we think we can really be differentiated, or a novel biology that we think would be truly innovative. So we're hoping to continue to,

41:47 you know, Pursue those efforts and announce those as we conclude some of those BD deals.

41:56 Thanks very much. Thanks, Josh. Thank you. And there are no other questions in the queue. I'd like to turn the call back to Sheila for any further remarks.

42:08 Well, thank you so much, everyone, for joining us on today's call. We are very excited that this is the Faheem Hasnain Bio's first earnings call.

42:15 We look forward to really getting together with you on a quarterly basis to show you all the progress that we're making and our ability to execute on our clinical programs. As we've always said, this is what we're trying to build, an innovative research and development engine that can really do a lot but in a very nimble and entrepreneurial way with high quality. And along those lines, I'd really like to thank the Gossamer Bio team for pulling together really all this amazing material and continuing to really support our efforts here. as well as the folks on the call. Thanks, everyone, and have a great day. Ladies and gentlemen, thank you for participating in today's conference. This concludes today's program. You may all disconnect. Everyone, have a great day.

Follow Gossamer Bio, Inc. into a list and get an email when it puts out news.

Latest news releases

Companies on this call

Speakers

Ying Hong

Analyst, Bank of America Merrill Lynch

Dr. Sheila Gujarati

Co-founder and Chief Executive Officer

Josh Shimmer

Analyst, Evacor

Bryan Giraudo

Chief Financial Officer

Joseph Schwartz

Analyst, SVB

More from Gossamer Bio, Inc.